The present narrative review discusses the burden of Premenstrual Dysphoric Disorder (PMDD) and highlights the lack of awareness by analyzing the following key points: -Prevalence and Diagnosis: PMDD affects a significant portion of women during their reproductive years, but diagnosis is often delayed due to limited understanding and awareness. -Mental Health Burden: PMDD increases the risk of suicide attempts and negatively impacts quality of life. There are also economic costs associated with absenteeism and healthcare use. -Cultural and Gender Perspectives: Societal stigma surrounding menstruation and mental health likely contributes to underdiagnosis. -Lack of Sex and Gender Perspective in the Healthcare System: Research bias towards male subjects and historical neglect of women’s health issues contribute to limited knowledge about PMDD. -Non-Intersectional Approaches: Disparities in access to healthcare and the unique experiences of women further complicate PMDD diagnosis and treatment. -Vicious Cycle: The lack of research and awareness creates a vicious cycle where PMDD remains misunderstood and inaccurately treated. Finally, it emphasizes the need for increased awareness, education, and research on PMDD, particularly with a gendered and intersectional optic. The situation in Latin America is presented as a particular concern due to a lack of recent data and potentially higher prevalence due to socioeconomic factors.

Cocaine use disorder (CUD) presents high comorbidity with mood symptoms that impair recovery processes and facilitate relapses. Peripheral brain-derived neurotrophic factor (BDNF) is negatively correlated with mood symptoms in depressive disorders. However, whether a correlation exists between BDNF and mood in CUD is still unknown. Thus, in this cross-sectional study, we explored the potential relationship between peripheral BDNF levels and depression and anxiety symptoms in CUD. Serum peripheral BDNF was determined by the ELISA method. Standardized Hamilton Depression (HDRS) and Anxiety (HARS) inventories were administered. Twenty-nine seeking-treatment CUD participants under stable medication (female = 3) were enrolled. According to the mood severity, 34.48% of participants were classified as normal, 24.14% as moderate, and 41.38% as severe symptoms (p < 0.001). Peripheral BDNF was similar between the different mood severity groups (p > 0.05). No correlation between BDNF and HDRS and BDNF and HARS was detected regardless of the severity of mood symptoms (p > 0.05). Different from what has been observed in depressive disorders, independence between peripheral BDNF levels and mood symptoms in CUD was observed. This finding suggests a singular, intricate regulation of peripheral BDNF and mood as part of CUD-related maladaptations that might disrupt the expected antidepressant response and perpetuate mood symptoms in CUD.